Excess βCTF, not Aβ: The culprit in Alzheimer-related endocytic dysfunction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 4, 2010, Pages 1263-1264

  Griffin, W Sue T ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; SECRETASE;

AGING; ALZHEIMER DISEASE; ENDOCYTOSIS; ENDOSOME; HUMAN; INFLAMMATORY DISEASE; NERVE CELL LESION; NERVE DEGENERATION; NONHUMAN; NOTE; PRIORITY JOURNAL; DOWN SYNDROME; GENETICS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; DOWN SYNDROME; ENDOSOMES; HUMANS; PEPTIDE FRAGMENTS;

EID: 76549119739     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0913922107     Document Type: Note

References (17)

1. Jiang Y, et al. (2009) Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA 107:1630-1635.
2. Griffin WS, et al. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611-7615.
3. Tanzi RE, et al. (1988) Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 331:528-530.
4. Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349-354.
5. Barger SW, Harmon AD (1997) Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388:878-881.
6. Mrak RE (2009) Neuropathology and the neuroinflammation idea. J Alzheimers Dis 18:473-481.
7. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM (1985) Alzheimer's disease in Down's syndrome: Clinicopathologic studies. Neurology 35:957-961.
8. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence ofneuropathological changes anddementia ofAlzheimer's disease in Down's syndrome. Ann Neurol 17:278-282.
9. Rovelet-Lecrux A, et al. (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24-26.
10. Sleegers K, et al. (2006) APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129:2977-2983.
11. Theuns J, et al. (2006) Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 78:936-946.
12. Wu C, Cui B, He L, Chen L, Mobley WC (2009) The coming of age of axonal neurotrophin signaling endosomes. J Proteomics 72:46-55.
13. Cataldo AM, et al. (2003) App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of Down syndrome. J Neurosci 23:6788-6792.
14. Salehi A, et al. (2006) Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51:29-42.
15. Li Y, et al. (2000) Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 20:149-155.
16. Barger SW, DeWall KM, Liu L, Mrak RE, Griffin WS (2008) Relationships between expression of apolipoprotein E and β-amyloid precursor protein are altered in proximity toAlzheimer β-amyloid plaques: Potential explanations fromcell culture studies. J Neuropathol Exp Neurol 67:773-783.
17. Nixon RA, Cataldo AM (2006) Lysosomal system pathways: Genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis 9 (Suppl 3):277-289.